- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 446 of 2,219.
| EudraCT Number: 2004-004488-31 | Sponsor Protocol Number: S-02005 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Rikshospitalet University Hospital, University of Oslo | ||
| Full Title: Does cyclosporine A reduce the insulin secretion from the pancreas? | ||
| Medical condition: Kidney failure / dialysis patients / transplantation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004222-93 | Sponsor Protocol Number: GPE 02 | Start Date*: 2006-11-28 |
| Sponsor Name:Curalogic A/S | ||
| Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated Grass (Phleum pratense) Pollen Extract (MGPE) in Subjects with Grass Pollen Allergy in a Randomized, Double-Blind, Placebo-Controlled... | ||
| Medical condition: Treatment of seasonal allergic rhinitis to grass pollen. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-000126-46 | Sponsor Protocol Number: ML20888 | Start Date*: 2007-11-05 | |||||||||||
| Sponsor Name:Roche Pharma AG | |||||||||||||
| Full Title: Einarmige, offene Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von monatlich subkutan verabreichtem C.E.R.A. an Patienten mit renaler Anämie, die noch nicht dialysepflich... | |||||||||||||
| Medical condition: renal anemia due to chronic kidney disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000135-26 | Sponsor Protocol Number: 2006-04-DOS-2 | Start Date*: 2007-06-08 | |||||||||||
| Sponsor Name:Hexal AG | |||||||||||||
| Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50... | |||||||||||||
| Medical condition: Persistent, moderate asthma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003493-97 | Sponsor Protocol Number: CP044/06/FCNS | Start Date*: 2007-04-30 | |||||||||||
| Sponsor Name:Archimedes Development Ltd. | |||||||||||||
| Full Title: A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthr... | |||||||||||||
| Medical condition: Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) CZ (Completed) FR (Ongoing) ES (Ongoing) IT (Ongoing) DE (Completed) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-001655-38 | Sponsor Protocol Number: MeFi/04/OBR-IBS/001 | Start Date*: 2006-03-06 |
| Sponsor Name:Menarini IFR – International Division | ||
| Full Title: Otilonium Bromide in Irritable Bowel Syndrome – (OBIS) Double blind, randomized, parallel group, placebo-controlled study to evaluate the effect of otilonium bromide on abdominal pain and quality o... | ||
| Medical condition: Irritable Bowel Syndrome | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) PT (Completed) DE (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-001175-38 | Sponsor Protocol Number: 6520-9170-08 | Start Date*: 2012-01-13 |
| Sponsor Name:MEDICE Arzneimittel Pütter GmbH & CO.KG | ||
| Full Title: A multi-center, randomized, double-blind,phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 0.5 % Cremogel vs vehicle on lesional skin in patients with mild ... | ||
| Medical condition: manifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-003106-24 | Sponsor Protocol Number: 721103 | Start Date*: 2011-10-06 |
| Sponsor Name:Baxter Innovations GmbH | ||
| Full Title: Effectiveness of PREFLUCEL vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older | ||
| Medical condition: To verify the effectiveness of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2011/2012 and 2012/2013 season respectively, manufactured us... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-003132-30 | Sponsor Protocol Number: BTXHH11 | Start Date*: 2011-09-09 | |||||||||||
| Sponsor Name:Svettmottagningen Hidroskliniken, Stockholm | |||||||||||||
| Full Title: Botulinum toxin treatment in craniofacial, inguinal, palmar, plantar and truncal hyperhidrosis, a randomized, double blind, placebo controlled study. | |||||||||||||
| Medical condition: Hyperhidrosis-craniofacial, inguinal, palmar, plantar and truncal. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001884-39 | Sponsor Protocol Number: CBEZ235ZIC01 | Start Date*: 2012-11-05 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa | |||||||||||||
| Medical condition: Adult patient with metastatic or unresectable malignant perivascular epithelioid cell tumors (PEComa) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001899-18 | Sponsor Protocol Number: OBI-1-302 | Start Date*: 2011-10-25 | |||||||||||
| Sponsor Name:Baxter Innovations GmbH | |||||||||||||
| Full Title: Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients with Congenital Hemophilia A With Factor VIII Inhibitors | |||||||||||||
| Medical condition: Congenital Hemophilia A with factor VIII inhibitors | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001900-36 | Sponsor Protocol Number: FFA115285 | Start Date*: 2011-09-26 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: FFA115285: A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate in... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-000585-36 | Sponsor Protocol Number: 6520-9959-02 | Start Date*: 2006-06-16 |
| Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG | ||
| Full Title: Placebokontrollierte multizentrische Doppelblindstudie bei Erwachsenen mit Methylphenidat retard bei tumorbedingter Fatigue | ||
| Medical condition: Tumorbedingte Fatigue | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-023508-28 | Sponsor Protocol Number: CAMN107GB05T | Start Date*: 2011-04-14 |
| Sponsor Name:Plymouth Hospital NHS Trust | ||
| Full Title: A CLINICAL TRIAL OF THE INTRA-TUMOURAL CONCENTRATION AND ACTIVITY OF NILOTINIB IN INTRA-CUTANEOUS SCHWANNOMAS | ||
| Medical condition: In vivo investigation of the intra-tumoural concentration and activity of nilotinib in cutaneous schwannomas (CS) in patienst with Neurofibromatosis 2 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002613-10 | Sponsor Protocol Number: STW5/212-D-011-III-V | Start Date*: 2012-11-29 | |||||||||||
| Sponsor Name:Steigerwald Arzneimittelwerk GmbH | |||||||||||||
| Full Title: A double-blind, randomised, placebo-controlled study on the efficacy of Iberogast® (STW 5) in patients with irritable bowel syndrome | |||||||||||||
| Medical condition: Irritable Bowel Syndrome (IBS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002640-27 | Sponsor Protocol Number: GED-301-01-11 | Start Date*: 2011-07-14 | |||||||||||
| Sponsor Name:GIULIANI | |||||||||||||
| Full Title: A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis) | |||||||||||||
| Medical condition: ACTIVE CROHN'S DISEASE | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024396-12 | Sponsor Protocol Number: CBEZ235C2201 | Start Date*: 2011-06-13 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | |||||||||||||
| Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024400-98 | Sponsor Protocol Number: V71_27S | Start Date*: 2011-02-24 | |||||||||||
| Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. | |||||||||||||
| Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2011-2012, when Administer... | |||||||||||||
| Medical condition: Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risk and ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024425-20 | Sponsor Protocol Number: Esperanz-002 | Start Date*: 2011-03-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Leiden University Medical Centre | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular car... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-024445-78 | Sponsor Protocol Number: MANS10 | Start Date*: 2011-02-28 |
| Sponsor Name:Magle AB | ||
| Full Title: Nicotine plasma concentrations and subjective effects of a single dose of Nicachet 4 mg nicotine oromucosal powder in pouch compared with 4mg Nicorette chewing gum and 1mg Nicorette nasal spray. | ||
| Medical condition: Smoking cessation | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.